Press Release

The collaboration will inform patient selection for treatment with STX-1, a first-in-class senolytic ADC directed against dipeptidyl-peptidase 4 (DPP4/CD26) as it progresses toward IND-enabling studies. Lille, France, January 27th, 2025 – StarkAge Therapeutics, a biotechnology company developing first-in-class senolytic antibody-drug conjugates (ADC) in age-related diseases, with an initial focus on oncology, today announced a research collaboration with Gustave Roussy, Europ

Presentations highlight therapy-induced senescence as a new therapeutic opportunity and reinforce the potential of STX-1 as a differentiated approach for solid tumors Lille and Villejuif, France, April 16, 2026 – StarkAge Therapeutics, a biotechnology company pioneering first-in-class senolytic antibody-drug conjugates (ADC) for age-related diseases with an initial focus on oncology, today announced that it will present two posters at the AACR Annual Meeting 2026. These data

• Reinforcing StarkAge’s transition toward IND-enabling and early clinical development for STX-1 • Florence Lhospice, PharmD, PhD, brings ADC and CMC expertise as well as a strategic leadership to advance Starkage pipeline • Eric Angevin, MD, PhD, seasoned early-development oncologist, adds rare, direct clinical expertise in DPP4-targeted therapies Lille, France – December 4, 2025 – StarkAge Therapeutics, a biotechnology company developing first-in-class senolytic antibody-dr

Lille, le 29 mai 2024. StarkAge Therapeutics, société de biotechnologie, annonce aujourd’hui une levée de fonds de 1,2 millions d’euros menée auprès de business angels, notamment des entrepreneurs en santé et de la BPI. La société, créée en 2018, est positionnée sur la recherche et le développement de thérapies dans le domaine de la senescence cellulaire avec pour objectif de lutter contre ses effets néfastes dans diverses maladies liées au vieillissement notamment les pathol